Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insights, Epidemiology and Market Forecast, 2027 - ResearchAndMarkets.com

June 14, 2018

DUBLIN--(BUSINESS WIRE)--Jun 14, 2018--The “Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The market of aSAH in 7MM was found to be USD 320.6 Billion in 2016

Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of aSAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of aSAH from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Aneurysmal Subarachnoid Hemorrhage Market Outlook

The aSAH market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Key Topics Covered:

1. Key Insights

2. Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Overview at a Glance

2.1. Market Share (%) Distribution of aSAH in 2017

2.2. Market Share (%) Distribution of aSAH in 2027

3. Disease Background and Overview: Aneurysmal Subarachnoid Hemorrhage

3.1. Introduction

3.2. Symptoms

3.3. Etiology and Risk Factors

3.4. Grading

3.5. Pathophysiology

3.6. Diagnosis

3.7. Biomarkers

3.8. Management

4. Epidemiology and Patient Population

4.1. Key Findings

5. 7MM Total Incident Patient Population of Aneurysmal subarachnoid hemorrhage

6. Country Wise-Epidemiology of Aneurysmal subarachnoid hemorrhage

6.1. Introduction

6.1.1. Total Incident Population of Aneurysmal Subarachnoid Hemorrhage

6.1.2. Sex-Specific Incidence of Aneurysmal Subarachnoid Hemorrhage

6.1.3. Grade wise Incidence of Aneurysmal Subarachnoid Hemorrhage

6.1.4. Diagnosed cases of Aneurysmal Subarachnoid Hemorrhage

7. Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs

9. Marketed drugs

9.1. Nymalize: Arbor Pharmaceuticals

10. Emerging Drugs

10.1. Key Cross Competition

10.2. SFX-01: Evgen

10.3. Clazosentan: Actelion Pharmaceutical

11. Aneurysmal Subarachnoid Hemorrhage (aSAH): 7 Major Market Analysis

12. Market Drivers

13. Market Barriers

14. Appendix

15. Capabilities

Companies Mentioned

Arbor Pharmaceuticals Evgen Actelion Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/w4xv9k/aneurysmal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006216/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs ,Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/14/2018 04:28 PM/DISC: 06/14/2018 04:28 PM


Update hourly